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Abstract. Aim: This study aimed to evaluate the efficacy of
aprepitant, a neurokinin (NK)1 receptor antagonist, on
chemotherapy-induced nausea and vomiting (CINV). Patients
and Methods: A randomized, open-labeled, parallel-design
study was undertaken in gynecologic-cancer (GC) patients at
the Fukuoka University Hospital. Twenty-three patients were
divided into without (group A) or with aprepitant (Group B)
in the first cycle of paclitaxel and carboplatin (TC) therapy.
From the second cycle onwards, all patients used aprepitant.
Statistical significance was assessed using McNemar and
Chi-square tests. Results: In the first cycle, the prevalence of
a complete response, no episodes of nausea or food intake in
group B was significantly increased compared to group A. No
significant difference in the prevalence of a complete response
or food intake situation was found from the second cycle
onwards. Conclusion: Combination of aprepitant with
standard anti-emetic therapy may contribute to prevention of
CINV in TC therapy for GC patients. 
Treatment with paclitaxel and carboplatin (TC) has been
recognized to be standard therapy in patients with
gynecologic-cancer (GC), including ovarian or endometrial
cancer (1-3). In cancer chemotherapy, nausea or vomiting are
the most distressing adverse effects. TC treatment is
classified as carrying a moderate emetic risk within
chemotherapy-induced nausea and vomiting (CINV) (4). 
In Japan, anti-emetic guidelines recommend administration of
a corticosteroid and a 5-hydroxytryptamine (HT)3 receptor
antagonist before moderately emetogenic chemotherapy
(MEC) to prevent CINV and to enhance the quality of life of
cancer patients during chemotherapeutic treatment (5-7).
However, the CINV owing to TC treatment tends to remain
uncontrolled despite administration of corticosteroid and a 5-
HT3 receptor antagonist. In general, CINV persists for 5 days. 
One recent study showed that CINV can be classified by
the onset period. That is, acute-phase CINV occurs within
24 h and delayed-phase CINV occurs 2-5 days after
administration of an anticancer agent (5-9). Conversely,
anticipatory nausea and vomiting can occur by conditioning
mechanisms in patients who have experienced nausea and
vomiting from chemotherapy (10). 
Aprepitant is a neurokinin (NK)1 receptor antagonist. It
represents a new class of anti-emetic agents and has a different
effect from 5-HT3 receptor antagonists (7, 8, 11-13). Such
NK1 receptor antagonists have demonstrated efficacy against
early (acute) and later (delayed) emesis (5). Several clinical
trials have reported NK1 receptor antagonists to be most
effective for highly emetogenic chemotherapy and MEC (3, 5-
7). However, there is less evidence to support the efficacy of
aprepitant in treatment regimens with MEC. To assess the
efficacy of NK1 receptor antagonists for CINV, we conducted
a randomized, open-labeled, parallel-designed, phase-II trial
of aprepitant in GC patients during adjuvant TC therapy. 
Patients and Methods
Study design. All patients provided written informed consent to
participate in this randomized, open-label, parallel-design study. The
Ethics Committee of the Fukuoka University Hospital (Fukuoka,
Japan) approved the study protocol.
Patient selection. The study focused on patients undertaking their
first TC therapy as postoperative adjuvant chemotherapy at the
Fukuoka University Hospital from November 2010 to October 2012.
Patients were excluded from the study if they: carried a risk of
vomiting for other reasons (symptomatic primary or metastatic
malignancy in the central nervous system, active peptic ulcer or
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gastrointestinal obstruction); had vomited in the 24 h before
treatment; had abnormal laboratory values (white blood cell count
<3,000/mm3, absolute neutrophil count <1,500/mm3, platelet count
<100,000/mm3, aspartate aminotransferase >2.5 × upper limit of
normal range (ULN), alanine aminotransferase >2.5 × ULN, total
bilirubin >1.5 × ULN or creatinine >1.5 × ULN. Patients under
systemic corticosteroid therapy (at any dose) or taking pimozide
were also excluded. In addition, patients who had the things (such as
ileus, taking opioid, apparent infection and more), which the doctor
judged to be unsuitable, were also excluded. Anti-emetic agents
could not be administered within 48 h before treatment.
Procedures. Twenty-three eligible patients were divided randomly
into two groups (A and B) using sealed opaque envelopes. Standard
anti-emetic therapy comprised of 3 mg of a 5-HT3 antagonist and
16 or 8 mg of dexamethasone administered via the intravenous
route on day-1 followed by dexamethasone (8 or 4 mg)
administered via the oral route on day-2 and day-3. Aprepitant
regimen consisted of aprepitant (125 mg) administered via the oral
route on day-1 and 80 mg on day-2 and day-3. Group A was treated
with standard anti-emetic therapy only. Group B was treated with
addition of aprepitant to standard anti-emetic therapy.
Dexamethasone was used for the prevention of drug
hypersensitivity, so we did not decrease its dose. From the second
cycle of TC treatment onwards, all patients were treated with
addition of aprepitant to standard anti-emetic therapy. 
Assessments. Patients recorded the onset of vomiting and nausea
in a symptom diary from day-1 to the morning of day-6.
“Vomiting” was defined as at least one episode of emesis or
gagging and was distinguished if emesis was not observed for at
least 1 min. With regard to nausea, patients recorded the most
severe intensity during the previous 24 h period based on a two-
point scale (“nausea” or “no nausea”). Food intake was recorded
based on a two-point scale (“eat as usual” or “not eat as usual”). If
rescue therapy was received, patients recorded the drug and day
of administration. Efficacy was evaluated from the start of
administration of the anti-tumor agent on day-1 (also defined as
“0 h”) to the morning of day-6 (“120 h”). The primary endpoint
was the percentage of patients with a complete response (CR),
which was defined as no emesis and no rescue therapy. Secondary
endpoints were either that the percentage of patients with CR in
the overall phase since second cycle or that CR or no episode of
nausea in the acute phase and delayed phase in all cycles. Safety
was evaluated using general laboratory tests. Adverse events (AEs)
were graded according to Common Terminology Criteria for
Adverse Events v4.0 set by the National Cancer Institute
(Bethesda, MD, USA). In each cycle of TC treatment, AEs were
recorded for the two groups. We compared CINV, rescue treatment
and food intake situation in groups A and B. Furthermore, we
compared CINV and rescue treatment in the first cycle and second
cycle of group A. Moreover, we compared the overall prevalence
of no episodes of nausea from two cycles to six cycles in groups A
and B. Furthermore, we noted if patients could not continue
chemotherapy. All patients received anti-emetic therapy based on
guidelines set in Japan. All patients recorded their symptoms each
day for six days. 
Statistical analyses. Statistical analyses were carried-out using the
McNemar test and Chi-square test. p-Values <0.05 were considered
significant.
Results
Twenty-six patients were enrolled in this study. Three
patients were excluded because of a hypersensitivity reaction
(HSR) against paclitaxel in the first cycle of TC treatment.
Finally, twenty-three patients were randomized and allocated
into two groups. Twelve patients were in the control group
(group A) and eleven patients were in the aprepitant group
(group B). Table I details the characteristics of patients in
each group. There were no differences in age, stage of
malignancy, alcohol consumption, smoking, motion sickness,
morning sickness and pre-treatment with CINV between
groups A and B. 
To evaluate alterations in CINV after TC treatment, we
compared the prevalence of a CR (no episodes of nausea
and no rescue therapy), no episodes of nausea and food
intake situation between the two groups in the first cycle of
TC treatment. In group B, all patients had a CR in acute,
delayed and overall phases. In overall and acute phases, the
prevalence of a CR in group B was significantly increased
compared to that in group A (p<0.05), whereas no
significant difference in the prevalence of a CR was seen
in the delayed phase (Figure 1A). In group B, all patients
had no episodes of nausea and all had good food intake
situation in overall, acute and delayed phases. In all phases,
the prevalence of patients with no episodes of nausea or
good food intake situation in group B was significantly
increased compared to that in group A (p<0.05) (Figure 1B
and C). These results suggested that addition of aprepitant
to standard anti-emetic therapy (5-HT3 receptor antagonist
and a corticosteroid) completely suppressed the CINV
mediated by MEC. 
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Table I. Patients’ characteristics.
Group A (n=12) Group B (n=11) 
Age 54.5±11.9 62.6±12.7
Primary diagnosis
Ovarian cancer 9 9
Endometrial cancer 3 2
Stage of malignancy
I 6 2
II 3 2
III 3 5
IV 0 2
Alcohol
None 9   11
A few in month 2 0
Every day 1 0
Smoking 2 0
Motion sickness 3 2
Morning sickness 3 2
Pretreatment for CINV 3 2
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Figure 1. Prevalence of patients in each treatment group who had a complete response in overall, acute and delayed phases. A: Prevalence of
patients who had a complete response. B: Prevalence of patients who had no episodes of nausea. C: Prevalence of patients who had good food
intake. *p<0.05 versus group A.
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Figure 2. Prevalence of patients in the first cycle and second cycle in group A. A: Prevalence of patients who had a complete response. B: Prevalence
of patients who had no episodes of nausea. C: Prevalence of patients who had good food intake. *p<0.05 versus the first cycle.
To confirm the efficacy of aprepitant on CINV, we
examined alterations in the prevalence of a CR, no episodes
of nausea and food intake situation between the first and
second cycles of TC treatment in both groups. In group A,
no significant difference in the prevalence of a CR or food
intake situation was found between the first and second
cycles of TC treatment, whereas addition of aprepitant
tended to augment the prevalence of a CR and good food
intake (Figure 2A and C). In the second cycle of TC
treatment, the prevalence of no episodes of nausea increased
significantly compared to that in the first cycle of TC
treatment in overall and delayed phases (p<0.05), whereas
there was little difference in the prevalence of no episodes
of nausea in the acute phase between the first and second
cycles of TC treatment (Figure 2B). In group B, the
prevalence of a CR, no episodes of nausea and food intake
situation in each phase was 100% in the first and second
cycles of TC treatment. Taken together, these results
suggested that addition of aprepitant improved CINV in
MEC. Furthermore, these results suggested that use of
aprepitant for CINV in the first cycle of TC treatment led to
clinically significant results. 
To further validate the continuous efficacy of aprepitant
for CINV during the first six cycles of TC treatment, we
compared alterations in the prevalence of a CR, no episodes
of nausea or food intake situation in each cycle of TC
treatment between groups A and B. In each cycle of TC
treatment, the prevalence of a CR (Figure 3), no episodes of
nausea (Figure 4) or food intake situation (Figure 5) in group
B was almost 100%, whereas the prevalence of these
parameters in group A did not reach 100%. In almost all
cases, the prevalence in group B increased significantly
compared to that in group A. These results suggested that
addition of aprepitant to standard anti-emetic therapy from
the first cycle of TC treatment may help to manage CINV.
Discussion
In the present study, we found that addition of the NK1
receptor antagonist aprepitant to standard anti-emetic therapy
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Figure 3. Comparison of the prevalence of a complete response between the overall phase and from two cycles to six cycles in groups A and B.
*p<0.05 versus group A.
(5-HT3 receptor antagonist and a corticosteroid) suppressed
CINV in overall, acute and delayed phases. Furthermore,
aprepitant used in combination was more efficacious than use
of a 5-HT3 receptor antagonist and a corticosteroid alone in
TC treatment. These data suggest that aprepitant is a
powerful and useful agent for preventing CINV in MEC. 
Aprepitant is a potent and selective non-peptide
antagonist of the NK1 receptor, which is known to play an
important part in CINV (5). In early clinical trials,
aprepitant was given in combination with a 5-HT3
antagonist- and dexamethasone-enhanced protection against
delayed emesis (12). This combination provided sustained
anti-emetic protection over multiple cycles of
chemotherapy and was, in general, well tolerated with few
AEs (9). In the present study, group B displayed no
episodes of nausea and no requirement for rescue treatment.
CINV tends to become more severe over multiple cycles
and the level of anti-emetic protection achieved in one
cycle of chemotherapy has been noted to affect the severity
of symptoms during, or even in anticipation of, subsequent
cycles (14). Therefore, CINV must be prevented in the first
cycle to decrease the risk of anticipatory nausea and
vomiting.
Paclitaxel is an anti-neoplastic drug widely used for GC
and thought to induce HSRs. In our study, three cases
suffered HSRs in the first cycle and one patient suffered
HSRs in the second cycle in the 26 cases enrolled in this
study. Therefore, these subjects needed to change to other
types of chemotherapy. HSR did not occur in group B, the
group in which aprepitant was added to standard anti-emetic
therapy from the first cycle onwards. In a recent study,
substance P was shown to be involved in paclitaxel-induced
HSRs (13). Substance P is the most likely endogenous ligand
for the NK1 receptor. Therefore, it was hypothesized that
aprepitant can prevent substance P-induced HSR and that an
aprepitant regimen is more effective than standard anti-
emetic therapy. However, in the present study, the prevalence
of a CR and no episodes of nausea in the first cycle and
second cycle were not significantly different between the two
groups. In addition, we assessed the number of patients who
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Figure 4. Comparison of the prevalence of no episodes of nausea between the overall phase and from two cycles to six cycles in groups A and B.
*p<0.05 versus group A.
completed six cycles. There was no significant difference
between the two groups in terms of five cycles and six
cycles. This result could have been because of the small
number of patients in the study. 
In conclusion, aprepitant used in combination with
standard anti-emetic therapy (5-HT3 receptor antagonist and
corticosteroid) was well-tolerated and more effective in
preventing the CINV associated with TC treatment. These
results suggest that CINV can be controlled using aprepitant
in combination with standard anti-emetic therapy from the
first cycle onwards.
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